These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
703 related articles for article (PubMed ID: 31698455)
1. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455 [TBL] [Abstract][Full Text] [Related]
2. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
4. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265 [TBL] [Abstract][Full Text] [Related]
5. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241 [TBL] [Abstract][Full Text] [Related]
6. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319 [TBL] [Abstract][Full Text] [Related]
7. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997 [TBL] [Abstract][Full Text] [Related]
8. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436 [TBL] [Abstract][Full Text] [Related]
9. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
10. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Larson RC; Kann MC; Graham C; Mount CW; Castano AP; Lee WH; Bouffard AA; Takei HN; Almazan AJ; Scarfó I; Berger TR; Schmidts A; Frigault MJ; Gallagher KME; Maus MV Nat Commun; 2023 Nov; 14(1):7509. PubMed ID: 37980341 [TBL] [Abstract][Full Text] [Related]
11. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. Lee L; Lim WC; Galas-Filipowicz D; Fung K; Taylor J; Patel D; Akbar Z; Alvarez Mediavilla E; Wawrzyniecka P; Shome D; Reijmers RM; Gregg T; Wood L; Day W; Cerec V; Ferrari M; Thomas S; Cordoba S; Onuoha S; Khokhar N; Peddareddigari V; Al-Hajj M; Cavet J; Zweegman S; Rodriguez-Justo M; Youg K; Pule M; Popat R J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399355 [TBL] [Abstract][Full Text] [Related]
12. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Cho SF; Anderson KC; Tai YT Front Immunol; 2018; 9():1821. PubMed ID: 30147690 [TBL] [Abstract][Full Text] [Related]
13. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Ng BD; Rajagopalan A; Kousa AI; Fischman JS; Chen S; Massa A; Elias HK; Manuele D; Galiano M; Lemarquis AL; Boardman AP; DeWolf S; Pierce J; Bogen B; James SE; van den Brink MRM Blood; 2024 Jul; 144(2):171-186. PubMed ID: 38579288 [TBL] [Abstract][Full Text] [Related]
14. Recent updates on CAR T clinical trials for multiple myeloma. Lin Q; Zhao J; Song Y; Liu D Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964 [TBL] [Abstract][Full Text] [Related]
15. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115 [TBL] [Abstract][Full Text] [Related]
16. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J Front Immunol; 2021; 12():609421. PubMed ID: 33767695 [TBL] [Abstract][Full Text] [Related]
17. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447 [TBL] [Abstract][Full Text] [Related]
18. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485 [TBL] [Abstract][Full Text] [Related]
19. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840 [TBL] [Abstract][Full Text] [Related]
20. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]